Author details

Full Name

David Brassat

Affiliation

ORCID

Career Start Year

1998

Papers

129

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
36588876	Progressive multifocal leukoencephalopathy genetic risk variants for pharmacovigilance of immunosuppressant therapies.		2022
36048016	Broader Epstein-Barr virus-specific T cell receptor repertoire in patients with multiple sclerosis.	J Exp Med	2022
36305889	Correction: Broader Epstein-Barr virus-specific T cell receptor repertoire in patients with multiple sclerosis.	J Exp Med	2022
32716690	Dimethyl fumarate treatment shifts the immune environment toward an anti-inflammatory cell profile while maintaining protective humoral immunity.	Mult Scler	2021
33903203	Serum Neurofilament Levels and PML Risk in Patients With Multiple Sclerosis Treated With Natalizumab.	Neurology: Neuroimmunology and NeuroInflammation	2021
33376202	Sunlight exposure exerts immunomodulatory effects to reduce multiple sclerosis severity.	Proc Natl Acad Sci U S A	2021
32516409	Identification of Umbre Orthobunyavirus as a Novel Zoonotic Virus Responsible for Lethal Encephalitis in 2 French Patients with Hypogammaglobulinemia.	Clinical Infectious Diseases	2021
33124504	BEST-MS: A prospective head-to-head comparative study of natalizumab and fingolimod in active relapsing MS.	Multiple Sclerosis Journal	2021
33269975	Oral nomegestrol acetate and transdermal 17-beta-estradiol for preventing post-partum relapses in multiple sclerosis: The POPARTMUS study.	Multiple Sclerosis Journal	2021
31148523	Frequency and characteristics of short versus longitudinally extensive myelitis in adults with MOG antibodies: A retrospective multicentric study.	Multiple Sclerosis Journal	2020
32934158	Author response: Prospective validation of the PML risk biomarker l-selectin and influence of natalizumab extended intervals.	Neurology	2020
31143968	What is the Relevance of the Systematic Use of Gadolinium During the MRI Follow-Up of Multiple Sclerosis Patients Under Natalizumab?	Clinical Neuroradiology	2020
31479149	Progressive Multifocal Leukoencephalopathy Incidence and Risk Stratification Among Natalizumab Users in France.	JAMA Neurology	2020
31043571	Teriflunomide treatment for multiple sclerosis modulates T cell mitochondrial respiration with affinity-dependent effects.	Science Translational Medicine	2019
29909771	Focal and diffuse cervical spinal cord damage in patients with early relapsing-remitting MS: A multicentre magnetisation transfer ratio study.	Mult Scler	2019
30654246	Single-arm study to assess comprehensive infusion guidance for the prevention and management of the infusion associated reactions (IARs) in relapsing-remitting multiple sclerosis (RRMS) patients treated with alemtuzumab (EMERALD).	Multiple Sclerosis and Related Disorders	2019
29722639	Efficacy of rituximab in refractory RRMS.	Multiple Sclerosis Journal	2019
31300547	Comparative effectiveness of teriflunomide vs dimethyl fumarate in multiple sclerosis.	Neurology	2019
31228536	MRI features of demyelinating disease associated with anti-MOG antibodies in adults.	Journal of Neuroradiology	2019
31081475	Neuraxial analgesia is not associated with an increased risk of post-partum relapses in MS.	Multiple Sclerosis Journal	2019
30915227	Oligoclonal bands increase the specificity of MRI criteria to predict multiple sclerosis in children with radiologically isolated syndrome.	Mult Scler J Exp Transl Clin	2019
30954932	Paraneoplastic neuromyelitis optica and ovarian teratoma: A case series.	Multiple Sclerosis and Related Disorders	2019
30665072	First clinical inflammatory demyelinating events of the central nervous system in a population aged over 70 years: A multicentre study.	Multiple Sclerosis and Related Disorders	2019
31439633	Prospective validation of the PML risk biomarker l-selectin and influence of natalizumab extended intervals.	Neurology	2019
29808469	MD1003 (High-Dose Pharmaceutical-Grade Biotin) for the Treatment of Chronic Visual Loss Related to Optic Neuritis in Multiple Sclerosis: A Randomized, Double-Blind, Placebo-Controlled Study.	CNS Drugs	2018
28903961	Paediatric optic neuritis: factors leading to unfavourable outcome and relapses.	British Journal of Ophthalmology	2018
30114625	Unexpected high multiple sclerosis activity after switching from fingolimod to alemtuzumab.	Multiple Sclerosis and Related Disorders	2018
30305850	Prolonged-release fampridine in multiple sclerosis: clinical data and real-world experience. Report of an expert meeting.	Therapeutic Advances in Neurological Disorders	2018
29676204	Neuromyelitis optica spectrum disorder mimicking extensive leukodystrophy.	Multiple Sclerosis Journal	2018
29606320	Recommendations for the use of Rituximab in neuromyelitis optica spectrum disorders	Revue Neurologique	2018
29695592	Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults: The MOGADOR study.	Neurology	2018
29741120	Late-onset neutropenia and neurological relapse, during long-term rituximab therapy in myelin oligodendrocyte glycoprotein-antibody spectrum disorder.	Multiple Sclerosis Journal	2018
28190705	Risk of autoimmune diseases and human papilloma virus (HPV) vaccines: Six years of case-referent surveillance.	Journal of Autoimmunity	2017
28959703	Radiologically isolated syndrome in children: Clinical and radiologic outcomes.	Neurology: Neuroimmunology and NeuroInflammation	2017
28506921	Decrease of blood anti-Î±1,3 Galactose Abs levels in multiple sclerosis (MS) and clinically isolated syndrome (CIS) patients.	Clin Immunol	2017
28681388	Matrix metalloproteinase 9 is decreased in natalizumab-treated multiple sclerosis patients at risk for progressive multifocal leukoencephalopathy.	Ann Neurol	2017
28616447	Natalizumab-PML survivors with subsequent MS treatment: Clinico-radiologic outcome.	Neurology: Neuroimmunology and NeuroInflammation	2017
28869673	Reply.	Annals of Neurology	2017
29141801	Treating asymptomatic bacteriuria before immunosuppressive therapy during multiple sclerosis: Should we do it?	Multiple Sclerosis and Related Disorders	2017
27028504	Assessment of a program to encourage the multidisciplinary management of urinary disorders in multiple sclerosis.	Neurourology and Urodynamics	2017
27885065	Effectiveness of mycophenolate mofetil as first-line therapy in AQP4-IgG, MOG-IgG, and seronegative neuromyelitis optica spectrum disorders.	Multiple Sclerosis Journal	2017
28261198	A Fas Lymphoproliferative Phenotype Reveals Non-Apoptotic Fas Signaling in HTLV-1-Associated Neuroinflammation.	Frontiers in Immunology	2017
27538659	Interleukin 17 alone is not a discriminant biomarker in early demyelinating spectrum disorders.	Journal of the Neurological Sciences	2016
26848486	Therapy with natalizumab is associated with high JCV seroconversion and rising JCV index values.	Neurology: Neuroimmunology and NeuroInflammation	2016
26928363	Teaching Video NeuroImages: Alternating skew deviation with abducting hypertropia following superior colliculus infarction.	Neurology	2016
27000224	Efficacy and safety profile of memantine in patients with cognitive impairment in multiple sclerosis: A randomized, placebo-controlled study.	Journal of the Neurological Sciences	2016
26826205	Comparative efficacy of fingolimod vs natalizumab: A French multicenter observational study.	Neurology	2016
26782333	CCR5 blockade for neuroinflammatory diseases--beyond control of HIV.	Nature Reviews Neurology	2016
26362900	Efficacy of rituximab in refractory neuromyelitis optica.	Multiple Sclerosis Journal	2016
26362898	A 10-year follow-up of the European multicenter trial of interferon Î²-1b in secondary-progressive multiple sclerosis.	Multiple Sclerosis Journal	2016